Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSPA5 | P11021 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.46 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 6/20 | 0.45 |
| ▸ | CA2 | P00918 | 6/20 | 0.45 |
| ▸ | IDO1 | P14902 | 2/20 | 0.45 |
| ▸ | CA9 | Q16790 | 4/20 | 0.43 |
| ▸ | MPO | P05164 | 1/20 | 0.43 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.43 |
| ▸ | HTR1A | P08908 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | GMNN | O75496 | 1/20 | 0.41 |
| ▸ | EGFR | P00533 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10568563 | 0.87 | HSPA5 (0.64) | HSPA5TSHRHIF1ACYP2D6ALDH1A1 | |
| SCHEMBL10534510 | 0.82 | MMP3 (0.51) | HSPA5TAAR1IDO1KEAP1KDM4E | |
| SCHEMBL28909080 | 0.82 | ALDH1A1 (0.46) | HSPA5TSHRHIF1ACYP2D6ALDH1A1 | |
| SCHEMBL29809738 | 0.82 | ALDH1A1 (0.56) | TSHRALDH1A1HPGDKDM4EEGFR | |
| SCHEMBL1945874 | 0.82 | ALDH1A1 (0.56) | TSHRALDH1A1HPGDKDM4EEGFR | |
| SCHEMBL4003141 | 0.80 | KEAP1 (0.63) | HSPA5TSHRHIF1ACYP2D6HPGD | |
| SCHEMBL7716799 | 0.79 | TRPA1 (0.45) | HSPA5ALDH1A1HPGDHTR1AHSD17B10 | |
| SCHEMBL31186853 | 0.79 | TRPA1 (0.45) | HSPA5ALDH1A1HPGDHTR1AHSD17B10 | |
| SCHEMBL2162646 | 0.77 | TAAR1 (0.54) | HSPA5TSHRHIF1ACYP2D6TAAR1 | |
| SCHEMBL30023384 | 0.76 | HSPA5 (0.54) | HSPA5TSHRHIF1ACYP2D6ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 273 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117229169-A | Preparation method of o-hydroxyphenylacetonitrile compound | 北京颖泰嘉和生物科技股份有限公司 | 2023-12-15 | — | — | CN | claimed |
| CN-116239483-A | Green synthesis method of phenylglycine | 江西兄弟医药有限公司 | 2023-06-09 | — | — | CN | claimed |
| CN-113209161-B | Sinomenium acutum fruit extract and preparation method and application thereof | 湖南农业大学 | 2023-05-23 | — | — | CN | claimed |
| CN-109912439-B | Method for continuously and rapidly preparing DL-phenylglycine and analogue thereof by using cyanohydrin method | 天宝动物营养科技股份有限公司 | 2022-09-23 | — | — | CN | claimed |
| CN-109824531-B | Method for continuously and rapidly preparing DL-phenylglycine and analogues thereof | 天宝动物营养科技股份有限公司 | 2022-08-23 | — | — | CN | claimed |
| CN-109912439-A | Method for continuously and rapidly preparing DL-phenylglycine and analogue thereof by using cyanohydrin method | 禄丰天宝磷化工有限公司 | 2019-06-21 | — | — | CN | claimed |
| CN-109824531-A | Method for continuously and rapidly preparing DL-phenylglycine and analogues thereof | 禄丰天宝磷化工有限公司 | 2019-05-31 | — | — | CN | claimed |
| CN-106380415-B | A kind of preparation method of D, L- phenylglycine and the like | 宁夏紫光天化蛋氨酸有限责任公司 | 2019-01-22 | — | — | CN | claimed |
| CN-106380415-A | Preparation method for D, L-phenylglycine and analogue thereof | 宁夏紫光天化蛋氨酸有限责任公司 | 2017-02-08 | — | — | CN | claimed |
| US-4378319-A | Process for the manufacture of aromatic cyanides | A. H. MARKS & CO., LIMITED (GB) | 1983-03-29 | — | — | US | claimed |
| US-4369322-A | WITH CYANOGEN CHLORIDE | DEGUSSA AG (DE) | 1983-01-18 | — | — | US | claimed |
| JP-6107539-A | — | — | None | — | — | JP | disclosed |
| JP-6228075-A | — | — | None | — | — | JP | disclosed |
| US-20260092045-A1 | SUBSTITUTED BENZOFURAN, BENZOPYRROLE, BENZOTHIOPHENE, AND STRUCTURALLY RELATED COMPLEMENT INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2026-04-02 | — | — | US | disclosed |
| US-12527779-B2 | Prostaglandin E2 (PGE2) EP4 receptor antagonists | DOMAIN THERAPEUTICS (FR) | 2026-01-20 | — | — | US | disclosed |
| US-3983160-A | Process for the preparation of hydroxyphenylacetonitriles | BAYER AKTIENGESELLSCHAFT (DT) | 1976-09-28 | — | — | US | disclosed |
| US-3983160-A | Process for the preparation of hydroxyphenylacetonitriles | BAYER AKTIENGESELLSCHAFT (DT) | 1976-09-28 | — | — | US | disclosed |
| US-3983160-A | Process for the preparation of hydroxyphenylacetonitriles | BAYER AKTIENGESELLSCHAFT (DT) | 1976-09-28 | — | — | US | disclosed |
| US-3961071-A | CARDIOVASCULAR DISORDERS, 1-PHENOXY-2-HYDROXY-3-TERT-BUTYLAMINO PROPANES | BOEHRINGER INGELHEIM GMBH (DT) | 1976-06-01 | — | — | US | disclosed |
| US-3940407-A | β-Adrenergic blocking agents in the 1,2,3-thiadiazole series | SYNTEX (U.S.A.) INC. (US) | 1976-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12527779-B2 | Prostaglandin E2 (PGE2) EP4 receptor antagonists | PTGER1, PTGER4, PTGER3 | HSPA5 4426/4885TSHR 606/4885HIF1A 365/4885 |
| US-20260092045-A1 | SUBSTITUTED BENZOFURAN, BENZOPYRROLE, BENZOTHIOPHENE, AND STRUCTURALLY RELATED COMPLEMENT INHIBITORS | TFPI, F3, BTK | HSPA5 2929/4885TSHR 904/4885HIF1A 4577/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.